MVX-ONCO-1: First in man, Phase I clinical trial combining encapsulation cell technology and irradiated autologous tumor cells for personalized cell-based immunotherapy. Safety, feasibility and clinical outcome results

被引：1
|
作者：
Migliorini, D. [1 ]
Vernet, R. [2 ]
Belkouch, M. C. [2 ]
Luy, P. [2 ]
Blaser, S. [1 ]
Ancrenaz, V. [1 ]
Blazek, N. [1 ]
Grandjean, N. [1 ]
Wasem, J. [1 ]
Janin, B. [3 ]
Harboe-Schmidt, P. [3 ]
Grogg, J. [3 ]
Bouche, N. [4 ]
Mach, N. [1 ,2 ]
机构：
[1] Fdn Dr Henri Dubois Ferriere Dinu Lipatti, Clin Res Unit, Geneva, Switzerland
[2] Ctr Oncol, Cell Therapy Lab, Geneva, Switzerland
[3] MaxiVAX SA, Clin Affairs, Geneva, Switzerland
[4] Ecole Polytech Fed Lausanne, Life Sci, Lausanne, Switzerland
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)30332-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
531
引用
收藏
页码：S114 / S114
页数：1
相关论文
共 22 条
  • [1] MVX-ONCO-1 phase 1 final results of the first personalized cell-based immunotherapy using cell encapsulation technology
    Mach, N.
    Vernet, R.
    Belkouch, M-C.
    Luy, P.
    Ancrenaz, V.
    Teta, P.
    Blazek, N.
    Grandjean, N.
    Wasem, J.
    Grogg, J.
    Perez, T.
    Migliorini, D.
    ANNALS OF ONCOLOGY, 2016, 27
  • [2] Cell-based immunotherapy combining encapsulation cell technology and irradiated autologous tumor cells: A novel technology platform that is both safe and feasible. Results from first in man trial
    Mach, N.
    Migliorini, D.
    Vernet, R.
    Belkouch, M. -C.
    Luy, P.
    Ancrenaz, V.
    Py, C.
    Grogg, J.
    Harboe-Schmidt, P.
    Bouche, N.
    ANNALS OF ONCOLOGY, 2015, 26 : 2 - 2
  • [3] A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors
    Vernet, Remi
    Fernandez, Eugenio
    Migliorini, Denis
    Ancrenaz, Virginie
    Charrier, Emily
    Belkouch, Marie-Claude
    Von Rohr, Olivier
    Urwyler, Muriel
    De Vito, Claudio
    Renaux, Jessica
    Villard, Jean
    Rubin, Olivier
    Grogg, Julien
    Mach, Nicolas
    CANCER RESEARCH COMMUNICATIONS, 2024, 4 (08): : 2089 - 2100
  • [4] Personalized Immunotherapy with Cell-Encapsulation Technology for 2nd line R/M HNSCC: Safety and Early Efficacy Data from all HNSCC patients treated with MVX-ONCO-1 in two clinical trials
    Fernandez, Eugenio
    Vernet, Remi
    Charrier, Emily
    Joerger, Markus
    Belkouch, Marie-Claude
    Urwyler, Muriel
    von Rohr, Olivier
    Rubin, Olivier
    Villard, Jean
    Ancrenaz, Virginie
    Grandjean, Nicole
    Lavalliere, Emmanuel
    Lafferma, Elisabeth
    Grogg, Julien
    Mach, Nicolas
    ORAL ONCOLOGY, 2021, 118
  • [5] Personalized immunotherapy with encapsulated cell technology: Feasibility, safety and efficacy results from the first-in-human clinical trial in advanced relapsing solid tumors
    Fernandez, E.
    Vernet, R.
    Charrier, E.
    Migliorini, D. M.
    Urwyler, M.
    Belkouch, M-C.
    Von Rohr, O.
    Saingier, V.
    Ancrenaz, V.
    Grandjean, N.
    Lafferma, E.
    Lavalliere, E.
    Rubin, O.
    Villard, J.
    Grogg, J. N.
    Mach, N.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S891 - S891
  • [6] Feasibility of iNKT cell and PD-1+CD8+T cell-based immunotherapy in patients with lung adenocarcinoma: Preliminary results of a phase I/II clinical trial
    Cheng, Xiaobo
    Wang, Jing
    Qiu, Chenli
    Jin, Yanling
    Xia, Bili
    Qin, Ran
    Hu, Huiliang
    Yan, Jia
    Zhang, Xiaoyan
    Xu, Jianqing
    CLINICAL IMMUNOLOGY, 2022, 238
  • [7] Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells:: preclinical results and outcome of a first clinical phase I/II trial
    Märten, A
    Flieger, D
    Renoth, S
    Weineck, S
    Albers, P
    Compes, M
    Schöttker, B
    Ziske, C
    Engelhart, S
    Hanfland, P
    Krizek, L
    Faber, C
    von Ruecker, A
    Müller, S
    Sauerbruch, T
    Schmidt-Wolf, IGH
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2002, 51 (11-12) : 637 - 644
  • [8] Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial
    Angela Märten
    Dimitri Flieger
    Sabine Renoth
    Silvia Weineck
    Peter Albers
    Markus Compes
    Björn Schöttker
    Carsten Ziske
    Steffen Engelhart
    Peter Hanfland
    Ludmila Krizek
    Cora Faber
    Alexander von Ruecker
    Stefan Müller
    Tilman Sauerbruch
    Ingo G. Schmidt-Wolf
    Cancer Immunology, Immunotherapy, 2002, 51 : 637 - 644
  • [9] SAKK 11/16, a phase IIa trial evaluating overall survival (OS) for recurrent/metastatic Head & neck squamous cell carcinoma (RMHNSCC) patients (pts) progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy
    Mach, N.
    Fernandez, E.
    Vernet, R.
    Vonrohr, O.
    Urwyler, M.
    Charrier, E.
    Belkouch, M. C.
    Saingier, V.
    Courtout, F.
    De Vito, C.
    Rubin, O.
    Ancrenaz, V.
    Grogg, J. N.
    Renaux, J.
    Gysel, K.
    Mueller, G.
    Brezina, T.
    Rordorf, T.
    Joerger, M.
    Michielin, O. A.
    ANNALS OF ONCOLOGY, 2023, 34 : S1286 - S1286
  • [10] Allogeneic dendritic cells fused with tumor cells:: Preclinical results and outcome of a first clinical phase I/II trial in patients with metastatic renal cell carcinoma.
    Märten, A
    Renoth, S
    Heinicke, T
    von Lilienfeld-Toal, M
    Schmidt-Wolf, IGH
    BLOOD, 2001, 98 (11) : 406A - 406A
123